Top Injectable Manufacturer in Lesotho – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 2 days ago
- 9 min read
Last Updated: September 4, 2026
TL;DR: Lesotho answers the question we always ask first — does the country keep a list of regulators it will rely on, and is India on it — with no list at all, and with a regulator that is still being built. The Lesotho Medicines and Medical Devices Control Authority Act of 2023 was brought into operation on 1 March 2026, replacing the 2008 framework, and the new authority is reported to be awaiting its regulations; no medicines register, guideline library or reference-authority list could be found. The only clause that touches India is the WHO's maturity list, on which India's CDSCO is level 3 for vaccines only, and Lesotho itself is not listed. Lesotho is a SADC member but not among the nine active ZaZiBoNa participants. The commercial gate is the National Drug Service Organisation in Mafeteng, a Ministry of Health trading body that approves suppliers before they may bid and now also procures for the church-run CHAL network. Out-of-pocket spending is 13% of health expenditure, tuberculosis incidence is 548 per 100,000, and India's own brief names pharmaceuticals as its leading export to the country.
Key Takeaways
No list, and a law that is weeks old in practice. The 2023 Act commenced on 1 March 2026 and is reported to await implementing regulations; the Act text itself could not be downloaded, so we describe it only from secondary summaries. We do not print an acronym for the new authority because sources disagree on its name, and we do not assert that a medicines register exists or that any product is currently registered.
The generic clause would not admit an Indian injectable. Lesotho is absent from the WHO's August 2026 list of authorities at maturity level 3 or 4, and CDSCO is on that list for vaccines only. Any Lesotho or regional rule that relies on maturity level 3 would therefore cover an Indian vaccine but not a small-molecule sterile injectable. Lesotho attended the 2025 Indian Pharmacopoeia policymakers' visit, which is a positive signal, not a rule.
The regional layer is membership without active participation. Lesotho is one of the sixteen SADC states and is a ZaZiBoNa member in name, but it is not among the nine authorities that actively assess dossiers jointly; it attended the June 2025 SADC GMP-inspection meeting. It is a member of the Southern African Customs Union, which means most goods physically clear through South Africa and the trade statistics reflect that.
The buyer is NDSO, and it approves suppliers first. The National Drug Service Organisation in Mafeteng procures, stores and distributes for government and other health institutions, sources from suppliers with GMP accreditation, and requires a supplier to apply for approval before bidding on its tenders and requests for quotation. The Ministry of Health has taken over medicines procurement for the CHAL church-hospital network, so that demand now flows through the same channel.
Introduction: Why Lesotho Demands a Premium Injectable Manufacturer in Lesotho
Every market in this series opens with the same question: does the country publish a list of regulatory authorities whose decisions it will lean on, and is India's CDSCO among them? Lesotho is the first market where the question arrives before the regulator has finished being created. The framework in force for most of the past two decades was the Medicines and Medical Devices Control Act of 2008; the WHO-derived country profile compiled for the African Medicines Regulatory Harmonisation programme recorded that as of 2008 there were no legal provisions requiring marketing authorisation for all pharmaceutical products on the market, no legal basis for a pharmacovigilance centre, and inspections that were lawful but not required. That is the baseline. The replacement, the Lesotho Medicines and Medical Devices Control Authority Act of 2023, was brought into operation by the Minister of Health on 1 March 2026, and the authority it establishes is reported to be awaiting its regulations, with the Ministry's budget for 2026 setting aside funds for the authority's offices.
We could not download the Act's text, so everything we say about its content comes from secondary summaries: that no medicine or device may be sold, manufactured, distributed, imported or exported unless registered and unless the person is licensed by the Board, that registration turns on safety, quality and efficacy, and that quality testing is to be done at the national quality-control laboratory or an accredited one. We do not print an acronym for the new authority because the sources we read call it three different things. No medicines register, no guideline library, no application portal and no list of reference or reliance authorities could be found, and we do not fill that gap with the plausible theory that Lesotho relies on South African registration, because we could not verify it. The answer to the standing question is therefore no list, with the regulator in transition, and a premium injectable manufacturer in Lesotho is one whose file is complete enough to be assessed under whichever regulations arrive.
What Sets a World-Class Injectable Manufacturer in Lesotho Apart
Because the national guideline does not yet exist in readable form, the practical standard is set by the regional and international layers. Lesotho is one of the sixteen SADC member states and is counted as a ZaZiBoNa member, but ZaZiBoNa distinguishes its nine actively participating authorities — Zambia, Zimbabwe, Botswana, Namibia, Tanzania, the Democratic Republic of the Congo, Malawi, Mozambique and South Africa — from the non-active members, and Lesotho is in the second group; it did attend the SADC good-manufacturing-practice inspection meeting of June 2025. The consequence for a supplier is that a dossier prepared to the ZaZiBoNa common standard, in CTD format with a WHO-format certificate of a pharmaceutical product and a current GMP certificate, is the file most likely to be accepted without rework whatever the new regulations say, because it is the file the neighbouring assessors already work from.
The one clause that reaches India is the WHO's maturity list, and it deserves precision. Lesotho does not appear on the WHO's August 2026 list of authorities operating at maturity level 3 or 4, and its actual benchmarked level is not published. India's CDSCO does appear, at level 3 for vaccines only, and so does South Africa's SAHPRA, also for vaccines only. A rule that admits products approved by a level-3 authority would therefore cover an Indian vaccine and would not cover a small-molecule sterile injectable from India, or, for that matter, one registered in South Africa. We have found no such rule in Lesotho, and we state this only so that a buyer reads any future reliance provision with the scope column of the WHO list in hand. Lesotho's deposit of its ratification of the African Medicines Agency treaty is recorded for 1 September as the twenty-third state, with the year not confirmed in the text we read; its PIC/S and AVAREF status we could not establish. We found no rule that singles out India at the border, and we do not assert that none exists.
Quality Systems Behind Every Injectable Supplied to Lesotho
For a sterile injectable the evidence any assessor or inspector expects is the same: aseptic process simulation records for the ISO Class 5 filling line, environmental monitoring trends, container-closure integrity, sterility and bacterial endotoxin testing by LAL, particulate matter, validated HPLC and GC assay and impurity methods, and ICH Q1A and Q1B stability data appropriate to a highland climate with cold winters and strong sunlight rather than data extrapolated from elsewhere. The 2023 Act is reported to route quality testing to the national quality-control laboratory or an accredited one, so the certificate of analysis for each batch should be written to be reproduced, with methods that a modest laboratory can run.
Lesotho's membership of the Southern African Customs Union with South Africa, Botswana, Namibia and Eswatini shapes the logistics and the statistics. Most consignments physically enter through South Africa and clear under the common external tariff, which is why the trade figures below disagree by direction and why cold-chain and temperature-excursion records should cover the road leg from Durban or Johannesburg as carefully as the air leg from India. National Drug Service Organisation states that it sources from suppliers with relevant GMP accreditation, and a WHO-GMP certificate with a recent inspection date is the document that answers that requirement.
Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry.
Why Farbe Firma is the Trusted Injectable Manufacturer in Lesotho for Global Buyers
Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than thirty countries. We build dossiers in CTD and ACTD format, the structure the ZaZiBoNa assessors and every SADC authority we have dealt with work from, so that the file is ready for whichever regulations Lesotho's new authority issues, and we supply the WHO-format certificate of a pharmaceutical product, the manufacturing licence and the GMP certificate as a matter of course. For a market where the regulator is being built, the more useful guarantee is a commercial one: complete supplier-approval documentation for NDSO, batch certificates of analysis written to be reproduced, and stability data for the climate the product will live in.
The bilateral relationship is small and pharmaceuticals lead it. India's Ministry of External Affairs brief of April 2026 records Indian exports to Lesotho of USD 10.30 million in 2024–25 against imports of USD 0.98 million, describes the trade as minimal, and names pharmaceuticals first among the major items India exports, ahead of rubber, plastics and machinery. Lesotho has accepted India's duty-free tariff preference scheme. In June 2025 Lesotho's Director of Clinical Services and the head of its medicines regulatory body visited India for the second policymakers' programme on the Indian Pharmacopoeia, and India's Minister of State made the first ministerial visit to Lesotho in a decade in July 2025. The only health memorandum the brief names is between Apollo Hospitals and the Ministry of Health; there is no regulator-to-regulator agreement. UN Comtrade tells two stories that we report separately and do not average: India reports pharmaceutical exports to Lesotho of USD 13.05 million in 2022, 5.60 million in 2023, 6.41 million in 2024 and 7.93 million in 2025, while Lesotho reports imports from India of 17.29 million, 7.80 million and 12.94 million for 2022 to 2024 — higher every year, consistent with goods that transit South Africa.
Where the money is: Lesotho has 2.36 million people, gross national income per capita of USD 1,280 in 2025, current health expenditure of about USD 123 per person and 12.6% of GDP in 2023, an unusually high share, and life expectancy of 57.8 years. Out-of-pocket payments were 13.2% of health expenditure in 2023, so the market is public and donor-financed rather than retail, and the National Drug Service Organisation in Mafeteng — the Ministry of Health's procurement, storage and distribution body, which publishes tenders and requests for quotation and requires suppliers to apply for approval before bidding — is the commercial gate; a SADC-funded electronic tendering portal for NDSO is in development. The Christian Health Association of Lesotho runs eight hospitals and 71 health centres and is reported to deliver more than 40% of care, and after shortages at its facilities the Ministry has taken over medicines procurement for them, so that demand now flows through NDSO too. Tuberculosis incidence was 548 per 100,000 in 2024, among the highest in the world though falling from 659 in 2018, and HIV prevalence among adults 17.1%; both sustain a steady requirement for sterile anti-infectives that a supplier can plan production around.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is India on Lesotho's list of recognised regulatory authorities?
No list was found. Lesotho's regulator is being re-established under the 2023 Act, in operation since 1 March 2026 and reported to await its regulations, and no reference-authority list, medicines register or guideline library could be located. The only clause that touches India is the WHO maturity list, on which CDSCO is level 3 for vaccines only and Lesotho is absent, so a level-3 rule would not admit an Indian small-molecule injectable. We neither claim nor deny that CDSCO would be recognised.
What law governs medicine registration in Lesotho now?
The Lesotho Medicines and Medical Devices Control Authority Act of 2023, brought into operation on 1 March 2026, replacing the 2008 framework. Secondary summaries describe a registration requirement for medicines and devices, licensing of persons by the Board, and quality testing at the national or an accredited laboratory; the Act text itself could not be downloaded and the implementing regulations are reported as pending, so format, language, fees, timelines and validity are not yet published.
Does Lesotho take part in ZaZiBoNa?
As a non-active member. All sixteen SADC states are counted as ZaZiBoNa members, but only nine — Zambia, Zimbabwe, Botswana, Namibia, Tanzania, the DRC, Malawi, Mozambique and South Africa — actively assess dossiers jointly, and Lesotho is not among them. It attended the June 2025 SADC GMP-inspection meeting. A dossier prepared to the ZaZiBoNa common CTD standard is nonetheless the safest file to bring.
Who buys injectables in Lesotho?
The National Drug Service Organisation, NDSO, in Mafeteng, the Ministry of Health's procurement, storage and distribution body, which sources from GMP-accredited suppliers, publishes tenders and requests for quotation, and requires suppliers to apply for approval before bidding. The Ministry has taken over medicines procurement for the CHAL church-hospital network, so that demand also flows through NDSO. Out-of-pocket spending is 13.2% of health expenditure, so the private retail channel is small.
Does Farbe Firma have experience with SADC and SACU markets?
Yes. Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries, several of them in southern Africa. We prepare dossiers in CTD and ACTD format, supply the WHO-format CPP, manufacturing licence and GMP certificate, and can document the cold chain from India through South Africa. Write to director@farbefirma.org with the product list and we will prepare the NDSO supplier-approval file.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments